MX2023005235A - Uricasa modificada y usos de la misma. - Google Patents

Uricasa modificada y usos de la misma.

Info

Publication number
MX2023005235A
MX2023005235A MX2023005235A MX2023005235A MX2023005235A MX 2023005235 A MX2023005235 A MX 2023005235A MX 2023005235 A MX2023005235 A MX 2023005235A MX 2023005235 A MX2023005235 A MX 2023005235A MX 2023005235 A MX2023005235 A MX 2023005235A
Authority
MX
Mexico
Prior art keywords
uricase
modified uricase
modified
contacting
polypeptide
Prior art date
Application number
MX2023005235A
Other languages
English (en)
Inventor
Ilya Ruderfer
Yakir Nataf
Gil Arvatz
Uri Hanania
Tamar Ariel
Shelly Rozen
Yael Hayon
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protalix Ltd filed Critical Protalix Ltd
Publication of MX2023005235A publication Critical patent/MX2023005235A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0093—Oxidoreductases (1.) acting on CH or CH2 groups (1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13013—Calcidiol 1-monooxygenase (1.14.13.13), i.e. 25-hydroxyvitamin D-1-alpha-hydroxylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención describe una uricasa modificada, así como un método para reducir el nivel de ácido úrico poniendo en contacto un medio con la uricasa modificada. La uricasa modificada comprende un polipéptido de uricasa entrecruzado por al menos un resto de unión bifuncional que comprende un resto de poli(alquilenglicol). El peso molecular del resto de enlace bifuncional es de aproximadamente 1.5 kDa a aproximadamente 4 kDa, y/o la uricasa modificada comprende una pluralidad de polipéptidos que poseen la secuencia de aminoácidos SEQ ID NO: 2. Asimismo. se describe un polipéptido que posee la secuencia de aminoácidos SEQ ID NO: 2. También se describe un proceso para preparar la uricasa modificada, que comprende poner en contacto el polipéptido con un agente de reticulación que comprende un resto de poli(alquilenglicol) y al menos dos grupos aldehído, para obtener un conjugado; y poner en contacto el conjugado con un agente reductor.
MX2023005235A 2020-11-03 2021-11-03 Uricasa modificada y usos de la misma. MX2023005235A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063108890P 2020-11-03 2020-11-03
PCT/IL2021/051305 WO2022097141A1 (en) 2020-11-03 2021-11-03 Modified uricase and uses thereof

Publications (1)

Publication Number Publication Date
MX2023005235A true MX2023005235A (es) 2023-10-16

Family

ID=78829449

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005235A MX2023005235A (es) 2020-11-03 2021-11-03 Uricasa modificada y usos de la misma.

Country Status (9)

Country Link
US (1) US20240002814A1 (es)
EP (1) EP4240423A1 (es)
JP (1) JP2023548496A (es)
KR (1) KR20230110281A (es)
CN (1) CN117098559A (es)
CA (1) CA3197108A1 (es)
IL (1) IL302628A (es)
MX (1) MX2023005235A (es)
WO (1) WO2022097141A1 (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
BR9808786A (pt) 1997-05-14 2000-07-11 Rhone Poulenc Rorer Pharma Composto peptìdio cìclico ou um seu sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, processos para tratar doenças associadas com a regulagem do cálcio em um paciente e para tratar a osteopenia ou a osteoporose em um mamìfero hospedeiro
JP5183836B2 (ja) 1998-08-06 2013-04-17 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Ｐｅｇ−尿酸酸化酵素結合体およびその使用
CA2338665C (en) * 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
ES2856881T3 (es) 2005-04-11 2021-09-28 Horizon Pharma Rheumatology Llc Formas variantes de urato oxidasa y su uso
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20080159976A1 (en) 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
NZ623294A (en) 2010-03-02 2015-10-30 Protalix Ltd Stabilized alpha-galactosidase and uses thereof
US20120328589A1 (en) 2010-03-02 2012-12-27 Ilya Ruderfer Glucocerebrosidase multimers and uses thereof
CN102634492B (zh) * 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
EP3294322A4 (en) 2015-05-15 2018-12-12 Medimmune, LLC Improved uricase sequences and methods of treatment
CN106226651B (zh) 2016-07-12 2019-08-23 国电南瑞科技股份有限公司 一种架空型故障指示定位终端及对地电压测量方法
JP2020530282A (ja) 2017-07-07 2020-10-22 アレナ ファーマシューティカルズ， インコーポレイテッド 組換えウリカーゼ酵素
US20190309269A1 (en) * 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating hyperuricemia and gout

Also Published As

Publication number Publication date
CN117098559A (zh) 2023-11-21
WO2022097141A1 (en) 2022-05-12
EP4240423A1 (en) 2023-09-13
US20240002814A1 (en) 2024-01-04
CA3197108A1 (en) 2022-05-12
KR20230110281A (ko) 2023-07-21
IL302628A (en) 2023-07-01
JP2023548496A (ja) 2023-11-17

Similar Documents

Publication Publication Date Title
Heller et al. Controlled release of water-soluble macromolecules from bioerodible hydrogels
US5061750A (en) Covalent attachment of anticoagulants and the like onto biomaterials
US6864327B2 (en) Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
Ikeda et al. Enzymatic oxidative polymerization of 4‐hydroxybenzoic acid derivatives to poly (phenylene oxide) s
JP2007520223A5 (es)
DK1025211T3 (da) Hyaluronansyntasegen og anvendelser deraf
NZ518143A (en) Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
DK141555B (da) Fremgangsmaade til fremstilling af baererbundne proteiner
DE60041715D1 (de) Verfahren zur herstellung von 1-benzotriazolcarbonatestern von wasserlöslichen polymeren
KR850003327A (ko) 물 분리제
JP2565363B2 (ja) トロンボゲンを形成しない基質の製造方法
Dey et al. Mimicking of chondrocyte microenvironment using in situ forming dendritic polyglycerol sulfate‐based synthetic polyanionic hydrogels
Caliceti et al. Physico-chemical and biological properties of monofunctional hydroxy teriminating poly (N-vinylpyrrolidone) conjugated superoxide dismutase
MX2023005235A (es) Uricasa modificada y usos de la misma.
SE0001309D0 (sv) Hydrogels and methods for their production
WO1994014460A1 (en) Method for crosslinking of haemoglobin and use of such crosslinked haemoglobin
DE69926145D1 (de) Polyarylenether-polyetherimid blends und verfahren zu ihrer herstellung
CN102643420B (zh) 一种异端基双官能团聚烷基醚类化合物及其用途
GB1403883A (en) Polymeric morpholine derivatives for gel permeation chromato graphy
JPS5599189A (en) Modified uricase free from antigenicity and its preparation
US7642323B2 (en) Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
CN110551303B (zh) 一种酶法制备柔性导电丝素蛋白膜的方法
ES469662A1 (es) Procedimiento para mejorar la capacidad de recepcion de va- por de agua de sustratos textiles
KR850004396A (ko) 네오카르지노스타틴 유도체의 제조방법
DK0934964T3 (da) Allophanatgruppeholdige polyurethan-polyacrylat-hybriddispersioner